Status:
NOT_YET_RECRUITING
Astragalus for Symptomatic Alleviation in High-grade Lymphoma
Lead Sponsor:
Bnai Zion Medical Center
Conditions:
High-grade Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Lymphoma is a malignant disease of the lymph nodes. There are different types of lymphoma: when some of the lymphomas are indolent and require only follow-up, in cases of aggressive lymphoma or indole...
Eligibility Criteria
Inclusion
- Age over 18
- Diagnosis of high-grade lymphoma
- Need to start treatment for lymphoma that includes chemotherapy as first line
- Possibility to answer questionnaires once a month
- Signing an informed consent form
Exclusion
- Taking up to a week before the randomization a drug with the potential for an interaction of major clinical significance with Astragalus according to a professional database
- Administration of chemotherapy in the past
- Significant disturbance in liver enzymes: Aspartate transaminase and/or alanine transaminase above 5 times the upper limit of normal
- Significant renal dysfunction: glomerular filtration rate under 30 ml/min according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
- Active autoimmune disease
- Pregnancy or breastfeeding
- Active participation in another interventional study
- Psychiatric disorder with impaired cognitive qualifications
Key Trial Info
Start Date :
August 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2032
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06510530
Start Date
August 1 2024
End Date
August 1 2032
Last Update
July 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bnai Zion Medical Center
Haifa, Israel, 3339419